About vascepa

 

 

 

Vascepa is the first FDA approved drug to reduce the risk of cardiovascular disease in patients with elevated triglyceride levels as a complementary therapy to the maximum tolerated dose of statins .

 

 

Vascepa is composed of high-purity icosapent ethyl, which is derived from omega-3 fatty acid, a natural fish oil component. Its production process uses FDA supervised manufacturing process to remove impurities and retain active ingredients.

 

 

 

Vascepa, a prescription drug, is recognized by FDA as a new chemical entity rather than a dietary supplement such as fish oil.

 

 

 

The unique clinical characteristics of vascepa have made it obtain many international patents, including the ability to reduce triglyceride level of patients without increasing LDL-C level.

 

 

 

Vascepa has been approved by the FDA to reduce triglyceride levels in patients with severe hypertriglycerides.

 

 

 

The efficacy and safety of vascepa was supported by a study of 8179 patients aged over 45 years with a history of coronary, cerebrovascular, carotid and peripheral artery occlusive diseases, or over 50 years with diabetes and other cardiovascular risk factors.

 

 

 

Patients treated with vascepa were significantly less likely to have cardiovascular events, such as a stroke or heart attack.